financetom
Business
financetom
/
Business
/
Mukesh Ambani, Satya Nadella chat: India has potential to become a premier digital society
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mukesh Ambani, Satya Nadella chat: India has potential to become a premier digital society
Feb 24, 2020 4:42 AM

Reliance Industries Chairman Mukesh Ambani on Monday said India is at the cusp of becoming a “premier digital society”, and will be among the top three economies of the world.

In conversation with Microsoft Chief Executive Satya Nadella at the Future Decoded CEO Summit, Ambani said the big change driving this transformation is the deepening of mobile networks that are working at a much faster pace than before.

"It all kickstarted in 2014 when PM gave us the vision of Digital India... 380 million people have migrated to Jio's 4g technology," he said.

Pre-Jio, the data speed was 256 kbps; and post-Jio, it is 21 Mbps, he pointed out.

Referring to US President Donald Trump's visit to the country, Ambani said India is much different than what it was during the visits of his predecessors Jimmy Carter, Bill Clinton or Barack Obama, and pointed out that mobile connectivity was a key change.

“I have no doubt in my mind that we will be among the top three economies in the world,” Ambani said, adding that the only debate which can exist is whether it happens in five or in ten years.

We in India have the opportunity to become the premier digital society, he stated.

"The next generation will see a very different India than what you (Nadella) and I have grown up in," he said.

Disclosure:

RIL, the promoter of Reliance Jio, also controls Network18, the parent company of CNBCTV18.com.

First Published:Feb 24, 2020 1:42 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Braze Fiscal Q4 Swings to Profit, Revenue Rises; Shares Gain After Hours
Braze Fiscal Q4 Swings to Profit, Revenue Rises; Shares Gain After Hours
Mar 27, 2025
04:53 PM EDT, 03/27/2025 (MT Newswires) -- Braze (BRZE) reported fiscal Q4 non-GAAP earnings Thursday of $0.12 per diluted share, compared with a loss of $0.04 a year earlier. Analysts polled by FactSet expected earnings of $0.05. Revenue in the three months ended Jan. 31 rose to $160.4 million from $131 million a year earlier. Analysts surveyed by FactSet expected...
Essential Properties Realty Trust Promotes Max Jenkins to COO
Essential Properties Realty Trust Promotes Max Jenkins to COO
Mar 27, 2025
04:53 PM EDT, 03/27/2025 (MT Newswires) -- Essential Properties Realty Trust ( EPRT ) said late Thursday that Max Jenkins has been promoted to chief operating officer. The company also said it promoted AJ Peil and Robert Salisbury to chief investment officer and head of corporate finance and strategy, respectively. ...
EXPLAINER-New creditors' battle emerges in Citgo auction reboot
EXPLAINER-New creditors' battle emerges in Citgo auction reboot
Mar 27, 2025
* New bidding round starts after year-long auction ended in shambles * Creditors' dispute over minimum bid to add more delays in 8-year-old case * Bondholders pact released at Gold Reserve ( GDRZF )-consortium's request * Bids by Venezuela-linked creditors turn auction into creditors game By Marianna Parraga HOUSTON, March 27 (Reuters) - A U.S. federal judge trying to move...
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug
Mar 27, 2025
04:46 PM EDT, 03/27/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday that the European Medicines Agency has validated its marketing authorization application for paltusotine, an oral treatment for endocrine disorder acromegaly. The marketing authorization application will now undergo review by the Committee for Medicinal Products for Human Use. This submission is supported by 18 clinical trials, including...
Copyright 2023-2025 - www.financetom.com All Rights Reserved